Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
9 evidence topics · 18 sources
Summary
Up to 50% of patients with GAD have an inadequate response to available agents, and 50 to 67% respond adequately to a first treatment trial. Reported response and remission rates are 60% to 68% and 30% to 36% with SSRIs and 56% to 58% and 31% to 38% with SNRIs; another review gives SSRI response in randomized trials as 60% to 75% against 40% to 60% with placebo. One source advises telling patients that treatment periods of up to 12 weeks may be needed to assess efficacy. SSRI and SNRI discontinuation rates are 20% to 23%, associated with nausea, sexual dysfunction, and slow onset. Across 28 anxiety disorder studies (n=5233), relapse prevalence was 36.4% in placebo groups and 16.4% in antidepressant groups; in 6 GAD studies, the odds ratio for relapse after discontinuation was 4.20 (95% CI 2.42 to 7.28). Benzodiazepines carry a class boxed warning for abuse, addiction, physical dependence, and withdrawal; pregabalin is a Schedule V controlled substance; buspirone efficacy beyond 3 to 4 weeks has not been demonstrated in controlled trials. The prescribing information of escitalopram, paroxetine, venlafaxine extended-release, duloxetine, and alprazolam lists GAD among their indications. The indication lists in the prescribing information of pregabalin, a recommended first-line therapy in one source, and of quetiapine extended-release, a second-line choice in the same source, do not include GAD.
Nonresponse to available treatments
“Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Response and remission rates with SSRIs and SNRIs
“However, numerous GAD patients do not achieve remission or response despite adequate dose and duration of SSRIs and SNRIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regularly, the rates of response and remission for GAD patients treated with SSRIs are 60%–68% and 30%–36%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, GAD patients treated with SNRIs have demonstrated response and remission rates of 56%–58% and 31%–38%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Delayed onset of antidepressant effect
Adverse effects, adherence, and discontinuation of antidepressants
“Additionally, several GAD patients discontinue the antidepressant therapy. Based on recent evidences, the overall discontinuation rates for SSRIs and SNRIs are 20%–23%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The low acceptability and tolerability of SSRIs and SNRIs are possibly associated with unfavorable side effects of SSRIs and SNRIs including nausea and sexual dysfunction, as well as slow onset of their action.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Patient concerns about tolerance and dependence
Relapse after antidepressant discontinuation
“The meta-analysis included 28 studies (n=5233) examining relapse with a maximum follow-up of one year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Discontinuation increased the odds of relapse compared with continuing antidepressants (summary odds ratio 3.11, 95% confidence interval 2.48 to 3.89).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Summary relapse prevalences were 36.4% (30.8% to 42.1%; n=28 studies) for the placebo group and 16.4% (12.6% to 20.1%; n=28 studies) for the antidepressant group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Subgroup | Studies | Odds ratio for relapse after discontinuation (95% CI) |
|---|---|---|
| Generalised anxiety disorder (DSM-IV) | “6”View highlighted excerpt for this quote | “4.20 (2.42 to 7.28)”View highlighted excerpt for this quote |
Treatment-resistant anxiety disorder: consensus definition
“The definition of pharmacological treatment resistance in anxiety disorders should rest on at least two failed trials of pharmacological monotherapy with first‐line agents approved for the treatment of anxiety disorders and recommended by guidelines (two different classes, e.g. one SSRI plus one SNRI, clomipramine or pregabalin, in the case of GAD) using at least the minimal approved dose, for the duration of at least 6‐8 weeks each, ideally with documented therapy adherence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This disorder is reportedly frequently under-recognized with less than one-third of patients being adequately treated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote